The US-based biotechnology company Napigen has been granted a patent (US11920140) from the US Patent and Trademark Office for the use of CRISPR technologies to edit organellar genomes. The patent's claims cover methods for altering the genomes of mitochondria or plastids. Napigen was recently awarded a grant from the USDA to develop a herbicide tolerance trait (see AgbioNews Mar 1, 2024).